Filing Flows › Century Therapeutics (IPSC) › Q4 2024
Century Therapeutics (IPSC) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 19, 2025
Century Therapeutics (IPSC) reported revenue of $4.2M for the fourth quarter 2024 (Q4 2024), up 16-fold from a year earlier and +428% from the quarter before. Operating margin was -893.5%, net loss $36.1M (864.4% of revenue).
Century Therapeutics, Q4 2024: revenue $4.2M (16× year over year), operating margin -893.5%, net loss $36.1M, operating cash flow −$24.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.2M | +428% | 16× |
| Operating profit | −$37.3M | — | — |
| Net earnings | −$36.1M | — | — |
| Operating cash flow | −$24.2M | — | — |
What changed
Revenue was $4.2M in Q4 2024, up 1457% year over year and up 428% from the previous quarter.
Operating costs exceeded revenue by $37.3M, an operating margin of -893.5%. Total costs fell 6% while revenue rose 1457%. The fastest-growing cost line was Research & development (+32%). The quarter ended with a net loss of $36.1M, wider than the previous quarter's $31.2M loss.
Operating cash flow was −$24.2M. Non-cash charges added back $3.3M of depreciation and $2.7M of share-based compensation. Working capital and other items added $5.9M.
Questions
What was Century Therapeutics' revenue in the fourth quarter 2024?
Century Therapeutics (IPSC) reported revenue of $4.2M for the fourth quarter 2024 (Q4 2024), up 16-fold from a year earlier and +428% from the quarter before.
Was Century Therapeutics profitable in the fourth quarter 2024?
Operating loss was $37.3M (-893.5% of revenue) and net loss $36.1M.